Homozygous cardiac myosin binding protein C-deficient (Mybpc t/t ) mice develop dramatic cardiac dilation shortly after birth; heart size increases almost twofold. We have investigated the mechanism of cardiac enlargement in these hearts. Throughout embryogenesis myocytes undergo cell division while maintaining the capacity to pump blood by rapidly disassembling and reforming myofibrillar components of the sarcomere throughout cell cycle progression. Shortly after birth, myocyte cell division ceases. Cardiac MYBPC is a thick filament protein that regulates sarcomere organization and rigidity. We demonstrate that many Mybpc t/t myocytes undergo an additional round of cell division within 10 d postbirth compared with their wild-type counterparts, leading to increased numbers of mononuclear myocytes. Short-hairpin RNA knockdown of Mybpc3 mRNA in wild-type mice similarly extended the postnatal window of myocyte proliferation. However, adult Mybpc t/t myocytes are unable to fully regenerate the myocardium after injury. MYBPC has unexpected inhibitory functions during postnatal myocyte cytokinesis and cell cycle progression. We suggest that human patients with homozygous MYBPC3-null mutations develop dilated cardiomyopathy, coupled with myocyte hyperplasia (increased cell number), as observed in Mybpc t/t mice. Human patients, with heterozygous truncating MYBPC3 mutations, like mice with similar mutations, have hypertrophic cardiomyopathy. However, the mechanism leading to hypertrophic cardiomyopathy in heterozygous MYBPC3 +/− individuals is myocyte hypertrophy (increased cell size), whereas the mechanism leading to cardiac dilation in homozygous Mybpc3 −/− mice is primarily myocyte hyperplasia.
Homozygous cardiac myosin binding protein C-deficient (Mybpc t/t ) mice develop dramatic cardiac dilation shortly after birth; heart size increases almost twofold. We have investigated the mechanism of cardiac enlargement in these hearts. Throughout embryogenesis myocytes undergo cell division while maintaining the capacity to pump blood by rapidly disassembling and reforming myofibrillar components of the sarcomere throughout cell cycle progression. Shortly after birth, myocyte cell division ceases. Cardiac MYBPC is a thick filament protein that regulates sarcomere organization and rigidity. We demonstrate that many Mybpc t/t myocytes undergo an additional round of cell division within 10 d postbirth compared with their wild-type counterparts, leading to increased numbers of mononuclear myocytes. Short-hairpin RNA knockdown of Mybpc3 mRNA in wild-type mice similarly extended the postnatal window of myocyte proliferation. However, adult Mybpc t/t myocytes are unable to fully regenerate the myocardium after injury. MYBPC has unexpected inhibitory functions during postnatal myocyte cytokinesis and cell cycle progression. We suggest that human patients with homozygous MYBPC3-null mutations develop dilated cardiomyopathy, coupled with myocyte hyperplasia (increased cell number), as observed in Mybpc t/t mice. Human patients, with heterozygous truncating MYBPC3 mutations, like mice with similar mutations, have hypertrophic cardiomyopathy. However, the mechanism leading to hypertrophic cardiomyopathy in heterozygous MYBPC3
+/− individuals is myocyte hypertrophy (increased cell size), whereas the mechanism leading to cardiac dilation in homozygous Mybpc3 −/− mice is primarily myocyte hyperplasia.
myosin binding protein C | cardiac dilation | cardiac hypertrophy | cytokinesis | hyperplasia D ilated cardiomyopathy (DCM) leads to heart failure and is a leading cause of morbidity and mortality (1, 2) . DCM is generally diagnosed as left ventricular (LV) dilation with associated reduction in cardiac contraction measured as impaired fractional shortening (3) . Hearts from affected individuals frequently demonstrate myocyte elongation, myocyte death, and fibrosis, in addition to LV dilation. DCM results from a variety of environmental factors, such as viral infection and alcohol abuse, as well as from mutations in a number of genes including titin, lamin A/C, cardiac actin, cardiac myosin heavy chain, and phospholamban (reviewed in refs. [4] [5] [6] . Whether all of these DCM-inducing factors activate the same or different cellular pathways to produce similar clinical features remains uncertain. The mechanisms by which mutations in the cardiac myosin binding protein C (MYBPC3) gene and other sarcomere protein genes lead to cardiac dilatation are under investigation.
MYBPC is a thick filament accessory protein component of the striated muscle sarcomere A band that constitutes 2-4% of the myofibril (discussed in ref. 7) . Although there are four Mybpc genes in the mammalian genome, only cardiac Mybpc (Mybpc3) is expressed in embryonic, neonatal, and adult hearts (8, 9) . Cardiac MYBPC interacts with at least four sarcomere components: myosin heavy chain, actin, myosin light chain 2, and titin (10) (11) (12) . More than 400 cardiac MYBPC3 gene mutations have been identified in patients as a cause of hypertrophic cardiomyopathy (HCM), an autosomal dominant disorder resulting from defective sarcomeres (for reviews, see refs. 12, 13). Due to an ancient founder mutation, 4% of the population of India carries a truncating MYBPC3 mutation (14, 15) . The majority of cardiac MYBPC3 mutations are predicted to encode truncated proteins that lack portions of either the carboxyl myosin and/or titin binding domains (7, 13) . These truncating MYBPC3 mutations are thought to cause cardiac hypertrophy by inducing myocyte hypertrophy (increased cell size), rather than myocyte hyperplasia.
We and other researchers have created mice that carry a mutant cardiac Mybpc3 gene to create murine HCM models (16) (17) (18) . Heterozygous mice, designated Mybpc t/+ , like humans bearing the same mutation, develop adult onset HCM. Homozygous MYBPC3 mutations are a much rarer cause of human DCM than autosomal dominant mutations in other sarcomere protein genes. However, homozygous Mybpc t/t mice that express two mutant alleles and no wild-type cardiac Mybpc3 develop LV dilation by 3 d postbirth and have all of the features of DCM, including LV chamber dilation, albeit mildly impaired fractional
Significance
We demonstrate that hearts lacking the sarcomere protein cardiac myosin binding protein C (MYBPC) undergo altered development due to an extra round of postnatal cell division. Normal cardiac myocytes replicate rapidly during fetal life, undergo a final round of cell division shortly after birth, cease dividing, and increase in cell size during prepubescent life. MYBPC has an unexpected function-inhibition of myocyte cytokinesis. MYBPC-deficient myocytes undergo an additional round of cytokinesis, resulting in increased numbers of myocytes and a greater proportion of mononuclear myocytes in neonatal hearts. Our findings provide insights into the mechanisms of dilated cardiomyopathy caused by homozygous mutations that reduce MYBPC levels.
shortening (16) . Unlike most humans with DCM, homozygous mutant cardiac Mybpc t/t mice have normal survival despite their cardiac disease. Other homozygous null cardiac Mybpc3 mice develop an identical phenotype (7, 17, 18) . Hence, for the studies described here, we assume that the phenotype of the Mybpc t/t mice is due to lack of MYBPC protein, rather than to small amounts of truncated protein. Recently, two groups have demonstrated that delivery of MYBPC to Mybpc3-null hearts restores cardiac function and morphology (19, 20) . Here, we have begun to dissect the mechanism by which homozygous Mybpc t/t hearts develop DCM.
Because Mybpc t/t mice begin LV dilation within a few days postbirth (16), we hypothesized that this reflected abnormal development of neonatal myocytes. During fetal and early perinatal development in wild-type hearts, cardiomyocytes divide rapidly, producing hyperplastic cardiac growth (21) . However, at 10 d postbirth, cardiomyocytes cease to divide and all subsequent increases in myocardial mass result from myocyte hypertrophy (22) . Despite the importance of this phenomenon, little is known about the molecular basis for the transition from hyperplasic to hypertrophic-based myocardial growth. We hypothesized that abnormal cardiomyocyte growth, either hyperplastic or hypertrophic, in the perinatal period accounted for the LV dilation of Mybpc t/t mouse hearts. To address this question, we have counted and measured cardiomyocytes from Mybpc t/t and wild-type mice. We have also studied the consequences of reducing MYBPC levels by injecting Mybpc3-specific shRNA at birth. Neonatal cardiomyocytes lacking cardiac MYBPC, due to Mybpc3-specific shRNA knockdown, undergo an additional round of cytokinesis. We conclude that dramatic reductions in the amount of cardiac MYBPC leads to aberrant cell cycle regulation at the G1/S checkpoint, resulting in at least one extra round of myocyte division and DCM.
Results

Increased Numbers and Immaturity of Cardiac Myocytes in Mybpc t/t
Mice. Cardiac tissues and myocytes from wild-type and Mybpc t/t mice were studied from birth to postnatal day 35 (designated as P0-35). The hearts from P5 Mybpc t/t mice had a significantly increased LV mass and LV/body weight ratio compared with wild-type mice ( Fig. 1 A and B and Fig. S1A ). Myocytes from P3 and P10 Mybpc t/t mice were 20-30% wider than wild-type myocytes ( Fig. S1 B and C) , which we presume reflects myocyte immaturity (23) and/or abnormal spacing between parallel sarcomeres due to MYBPC deficiency (24) . There was no significant difference in the length of myocytes from wild-type and Mybpc t/t mice (Fig. S1D ). As expected (22, 25, 26) , nearly all wild-type adult LV myocytes were binuclear ( Fig. 1 C-E) . Analyses of younger mice confirmed this finding. At P21, ∼5% of wild-type and heterozygous Mybpc t/+ LV myocytes were mononuclear and 90% were binuclear (Fig. 1E) 1E ; WT:Mybpc t/+ :Mybpc t/t , 5.8%:6.7%:18.3%; P < 4E-5). We defined myocyte numbers and nuclear morphology in hearts from 5-wk-old Mybpc t/t and wildtype mice by immunohistochemical staining of 10 sections evenly distributed across the LV. Wheat germ agglutinin (WGA) was used to demarcate plasma membrane boundaries ( Fig. 2 A and  B) , and nonmyocytes were excluded by size and absence of cardiac troponin I staining. In comparison with wild-type, Mybpc t/t LV contained ∼40% more myocytes than wild-type LV ( Fig. 2C ;
Previous studies have demonstrated that by P10 the majority of wild-type binuclear myocytes have exited the cell cycle (27) . We hypothesized that the increased proportion of mononuclear to binuclear myocytes in Mybpc t/t hearts reflected either premature cell cycle arrest before becoming binuclear or alternatively that mutant myocytes had continued cell cycle progression with cytokinesis-a delay in cell cycle exit that would account for greater myocyte number. To distinguish these models, we used three approaches to study cell cycle progression.
Mybpc t/t Myocytes Have Delayed Cell Cycle Exit. We injected the thymidine analog 5-ethynyl-2'-deoxyuridine (EdU) (28) into wild-type and Mybpc t/t neonates at P1 through P5 and assessed DNA synthesis in isolated P14 myocytes (Fig. 1D) . In comparison with wild type, there were significantly more EdU-positive mono-and binuclear myocytes from Mybpc t/t mice (47.02 ± 2.50% vs. 29.35 ± 3.06%; P = 0.0003; four mice per genotype; 200-300 cells per mouse). To identify cells undergoing mitosis, we used an anti-histone H3 phosphorylation (pH3) antibody that detects pH3 of serine residue 10 during the mitotic (M) phase of the cell cycle (29) . Immunohistochemistry analyses of pH3 at P3, P7, and P10 ( Fig. 3 A and B) indicated almost twice as many myocytes undergoing mitosis in Mybpc t/t than in wild-type hearts. Finally, we performed immunostaining for Aurora B kinase (Aurora B), which localizes to the central spindle during anaphase and in the midbody during cytokinesis (30 was localized to the cytoplasmic bridge between daughter cells ( Fig. 3 C and D) . Based on the increase in EdU incorporation and pH3 and Aurora B immunostaining in Mybpc t/t mice, we concluded that mutant myocytes have delayed cell cycle exit during neonatal life and undergo additional rounds of cell division. As a result, Mybpc t/t mice had both more myocytes and more mononuclear myocytes than wild-type hearts.
To further assess cell cycle regulation in neonatal (P10) Mypbc t/t LV, we assessed expression of cell cycle-related genes by RNAseq (Table S1 ). One hundred and seven genes that are described as "cell division," "cyclin-associated," or "cell cycle" genes are expressed in the wild-type P10 LV. Expression of 70 cell cycle-related genes either increased or decreased (P < 0.001), whereas 38 of the cell cycle-related genes were expressed at similar levels in wild-type and Mypbc t/t LV. Presumably these cell cycle-associated gene expression changes are related to changes in cell cycle exit found in neonatal Mypbc t/t LV.
Neonatal Depletion of Cardiac MYBPC Impairs Myocyte Maturation in
Wild-Type Mice. To confirm that altered myocyte maturation in Mybpc t/t hearts was due to the myocyte-autonomous deficiency of MYBPC, we used the cardiotropic adeno-associated virus serotype 9 (AAV9) (31, 32) to deliver Mybpc3-specific shRNA to the neonatal heart. Two Mybpc3-specific shRNAs that targeted different regions of Mybpc3 RNA (Fig. S2A ) were constructed with a colinear EGFP reporter gene downstream of the cardiac troponin T (cTnT) promoter, so as to exclude nonmyocyte expression (Fig. S2B) .
AAV9-Mybpc3-shRNA was injected into the thoracic cavity of P1 wild-type neonates [5 × 10 13 viral genomes (vg)/kg], and EGFP fluorescence was assessed to monitor shRNA expression. Cardiac EGFP fluorescence was detected 48 h after virus injection and continued for at least 5 mo (Fig. 4A ) but was absent from all other organs (33) . EGFP fluorescence was present in 60-80% of adult myocytes isolated from viral-transduced mice (Fig. 4B) . Both of these shRNA constructs (denoted AAV9-Mybpc3-shRNA) had comparable efficiency in attenuating in vivo Mybpc3 RNA expression (Fig. 4C) .
Four weeks after viral injection, EGFP-positive myocytes were isolated, and nuclear morphology was examined. Wild-type mice infected with a control shRNA (that targeted LacZ RNA; Materials and Methods) had ∼5% mono-and 90% binuclear myocytes (Fig.  4D ). Among EGFP-positive myocytes, wild-type hearts injected with Mybpc3-specific shRNA had 5-6-fold more mononuclear myocytes than hearts injected with control shRNA (Fig. 4D ). Mice infected with either of the two distinct Mybpc3-specific shRNA constructs showed similar results (Fig. 4D ).
Myocyte Proliferation After Cardiac Injury in Mybpc t/t Mice. We considered whether Mybpc t/t mice have better cardiac regenerative capacity after injury than wild-type mice, as myocyte division may play an important role in regeneration. To test this hypothesis, we performed sham or LV apical resections (26, 34) , excising ∼15% of the total LV mass in P10 wild-type and Mybpc t/t mice ( Fig. 5 A-I ). There is no difference in survival of the two genotypes after apical resection. Surviving neonates received a BrdU pulse 1 d later, and at P17 BrdU incorporation was assessed in hearts stained with cTnT-specific antibody, to exclude nonmyocytes, and with Ki67 antibody to detect cell cycle activity ( Fig. 5 J and K (Fig. S3) . Dystrophic calcification also occurred in both apical and basal regions when apical resection was carried out in P1 Mybpc t/t mice (Fig. S4) . We suggest that Mybpc t/t hearts were more susceptible to necrotic death after resection due to altered biomechanical properties that increased energy requirements due to enhanced actomyosin force (35) and/or elevated wall stress (24) in Mybpc t/t myocytes. Mypbc t/t mice appear to have reduced regenerative capacity compared with wild-type mice.
Discussion MYBPC is critical for normal cardiac structure and function. Absence of MYBPC in the adult heart compromises the stiffness and rigidity of myofilaments (36, 37) , reduces sarcomere packing density (24) , and perturbs contractile performance (16) , which might account for increased myocyte width in Mybpc t/t mice and contribute to increased LV wall thickness ( Fig. S1 C and D immature, based on dimensions and a single nucleus, unlike postnatal wild-type myocytes. During neonatal development, Mybpc t/t myocytes undergo additional rounds of division, resulting in increased myocyte numbers in Mybpc t/t hearts (Fig. 6 ). Given its established role in myofilament lattice rigidity (1, 7, 12, 17, 18, 24) , we conclude that MYBPC is critical for inhibiting postnatal myocyte cytokinesis, an essential step in myocyte maturation accompanying cell cycle exit.
To progress through the cell cycle, myocytes must disassemble both the cytoskeleton and the contractile apparatus, the thick and thin myofilaments of the sarcomere. High-resolution confocal microscopy of immunostained neonatal myocytes has identified two phases of sarcomere dissolution. Before metaphase, proteins in the z disk and thin filament disassemble, whereas thick filament proteins, including myosin and MYBPC, maintain a mature, cross-striated pattern. Late in anaphase, thick filament proteins disassemble and remain dispersed until cytokinesis is complete (38) .
Before cell cycle exit, neonatal mouse myocytes undergo karyokinesis without cytokinesis (39, 40) . This phase in myocyte maturation is characterized by synchronized changes in the expression of cell cycle molecules; levels of activators (Cdk2, Cdk3, Cdk4, Cdk cofactors, and Ccnd1) are decreased, and levels of inhibitors (p21, p27KIP1, TSC2, p130, and Rb) are increased. Transgenic overexpression or genetic depletion in the heart of some cell cycle regulators (27, 41) has been demonstrated to partially overcome neonatal myocyte cell cycle arrest and enable additional rounds of cell division. Recent studies demonstrate that these reciprocal events are mediated in part by the transcriptional activator 14-3-3e (42), the transcription factor Meis1 (43) , and activation of the DNA damage response pathway induced by reactive oxygen species in neonatal mice (44) .
MYBPC deficiency also impacted the regenerative capacity of the P10 mouse heart. Apical resection did not increase BrdU incorporation or Ki67 staining among cTnT-positive cells in Mybpc t/t mice as it did in wild-type mice ( Fig. 5 and Fig. S3 ). Moreover, as resected Mybpc t/t hearts showed necrosis and dystrophic calcification, we suspect that MYBPC-deficient myofilaments are less resistant to sheer forces and perhaps more susceptible to depolymerization, as has been seen ex vivo (36, 45) . These observations hint at the dichotomy inherent in a rigid sarcomere, a structure that can support the stress of contraction but that also impedes myocyte regeneration. The findings presented here suggest two independent mechanisms by which MYBPC3 mutations can alter cardiac morphology. Individuals carrying heterozygous MYBPC3 mutations develop HCM (46) , characterized by cardiac hypertrophy (increased heart mass and altered morphology). These changes in size and shape are due, at least in part, to the increased size of myocytes (hypertrophy) (47) . By contrast, individuals homozygous for MYBPC3 mutations develop cardiac dilation, which we conclude is due to myocyte hyperplasia (increased numbers of myocytes). This myocyte hyperplasia is associated with increased numbers of mononuclear myocytes that may have reduced contractile function. Defining the relationship of homozygous MYBPC3 DCM to other more common forms of DCM will provide further insights into this clinically important pathophysiology.
Materials and Methods
Mouse Studies. All mouse studies were performed with approved protocols in compliance with the Association for the Assessment and Accreditation of Laboratory Animal Care and Harvard Medical School. Mybpc t/t (16) and wildtype mice (129SvEv background) were studied. The Mybpc t/t alleles contain a PGK-neomycin resistance gene that disrupts exon 30 and is predicted to encode from a truncated peptide that terminates with amino acid residue 1,064 of the 1,270 residues in wild-type cardiac MYBPC. Protein chemical studies have demonstrated that this allele produces less than 10% of the normal amount of cardiac MYBPC.
Myocyte Isolation. Ventricular myocytes were isolated from P1 to P10 mice using a modified collagenase dissociation protocol. After anesthetizing mice [2% (vol/vol) isoflurane inhalation], the thoracic cavity was opened and LV was perfused (2 mL/min) with prewarmed 37°C buffer (126 mM NaCl, 4.4 mM KCl, 1 mM MgCl 2 , 4 mM NaHCO 3 , 30 mM 2,3-butanedione monoxime, 10 mM Hepes, 11 mM Glucose, 0.5 mM EDTA) with 0.09% Collagenase Type I (Worthington), 0.125% Trypsin, and 25 μM CaCl 2 for 2 min. The perfused heart was then excised and placed in buffer with 100 μM CaCl 2 and 2% BSA for 10 min at 37°C. Ventricular tissue was minced, and myocytes were dispersed by gentle trituration of minced tissue through a wide bore disposable serologic pipette. The dispersed cells were filtered through a 100 μm nylon mesh and washed twice by centrifugation (50 × g for 3 min). The resulting cell pellet was suspended in 1 mL buffer with 100 μM CaCl 2 and fixed by the addition of 1 mL 2% (wt/vol) paraformaldehyde in PBS and incubated on ice for 20 min. Fixed myocytes were washed twice in PBS by centrifugation (50 × g for 3 min) and stored at 4°C.
For ventricular myocyte isolation from 3-4-wk-old mice, immediately after sacrifice, hearts were excised, the ascending aorta was quickly cannulated, and the hearts were perfused for 5 min with warm (37°C) calcium Tyrode's buffer (135 mM NaCl, 4 mM KCl, 0.33 mM NaH 2 PO 4 , 1.2 mM MgSO 4 , and 10 mM Hepes, pH 7.40), followed by 10-15 min of perfusion with collagenase B (0.56 mg/mL, Roche), collagenase D (0.48 mg/mL, Roche), and protease XIV (0.07 mg/ml, Sigma). The hearts were minced and filtered as described above. Cells were plated onto laminin-precoated coverslips (1 μg/cm 2 ; Invitrogen) and cultured for 1 h in MEM (Sigma) containing 10 mM 2,3-butanedione monoxime to extract myocytes from other cardiac cells.
Immunohistochemistry. Histochemical analyses were performed on heart sections fixed in 4% (wt/vol) paraformaldehyde overnight. Sections were treated with xylene (to remove paraffin), rehydrated, and permeabilized in 0.1% (vol/vol) Triton-X100 in PBS. Sections were incubated with primary antibodies applied at Myocyte Quantification. WGA-stained heart sections were imaged using a Zeiss confocal microscope, and images were processed after color inversion, so that individual cells were highlighted as "particles." The "Watershed" algorithm (Fiji; fiji.sc/) was used to resolve distinct particles that were close together. Particles were included based on the size of cardiomyocytes ranging from 150 to 3,000 pixels/cell.
AAV Production and Purification. AAV vectors were packaged into AAV9 capsid by the triple transfection method using helper plasmids pAdΔF6 and plasmid pAAV2/9 (Penn Vector Core). We used 50 μg of plasmid DNA per 15-cm cell culture plate. Three days after transfection, AAV vectors were purified in Optiprep density gradient medium (D-1556, Sigma) by centrifugation and stored at −80°C. shRNA Vector Construction. Two shRNA constructs specific for 21-base-pair sequences corresponding to cardiac Mypbc3 were constructed. The following targeted sequences were used: Mypbc3-specific shRNA-1, ccagagaaggcagaatctgaa; Mypbc3-specific shRNA-2, aagggtttgcctgcaacctgt; and shRNA control targeting LacZ, gactacacaaatcagcgattt.
RNA-Seq. Hearts from mice were rapidly isolated, placed in room temperature PBS to evacuate blood, and then immersed in RNALater (Qiagen) at room temperature. We used 2 μg of total ventricular RNA to construct RNAseq sequencing libraries (48) . At least 20 million 50-bp paired-end DNA reads were obtained from each library using the Illumina HiSeq2500. Data were processed as previously described (48) .
Apical Resection. LV apical resection procedures were performed as described (26) . In brief, mice were anesthetized on ice to induce deep transient sedation, apnea, and asystole. The thoracic cavity was opened at the fourth intercostal space and the LV exposed. Approximately 15% of the ventricular apex was resected. Successful apical resection was assessed by visualization of the ventricular chamber immediately after resection. Following surgery, mice were rapidly warmed and monitored for viability. Sham-operated mice underwent identical procedures but without LV apex resection. We have independently verified that robust heart regeneration occurs in the neonatal mouse apical resection model (34) .
EdU/BrdU Labeling. To assess DNA synthesis in isolated myocytes, neonatal pups received an i.p. injection of EdU (Life Technologies, C10339, 5 mg/kg) for the first 5 d. To label cells with ongoing DNA synthesis, surviving mice subjected to sham or apical-resection surgery received a pulse (two s.c. injections 12 h apart) of BrdU (Sigma, 20 mg/mL solution in sterile PBS, 100 mg/kg dose) on the first day post-resection.
Statistical Analyses. Significance was assessed by two-sample Student's t test on selected groups, assuming two-tail heteroscedastic distributions. Multiple group comparison was assessed by ANOVA. Chr, chromosome; end, mm9 base pair position; fold, fold difference between WT and Mybpc t/t gene expression at P10; P value, probability that the difference between Wt and Mybpc t/t gene expression would occur by chance; start, mm9 base pair position. WT (wild-type) and Mybpc t/t RNA expression of selected cell cycle genes is presented in reads per mapped reads.
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